SPDR S&P Biotech ETF (NYSEARCA:XBI) Stock Position Reduced by Hanson & Doremus Investment Management

Hanson & Doremus Investment Management lessened its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 27.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,579 shares of the exchange traded fund’s stock after selling 1,346 shares during the quarter. Hanson & Doremus Investment Management’s holdings in SPDR S&P Biotech ETF were worth $322,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hartline Investment Corp increased its holdings in SPDR S&P Biotech ETF by 2.0% in the third quarter. Hartline Investment Corp now owns 5,502 shares of the exchange traded fund’s stock worth $544,000 after buying an additional 106 shares during the last quarter. Signature Estate & Investment Advisors LLC increased its stake in shares of SPDR S&P Biotech ETF by 5.7% during the 3rd quarter. Signature Estate & Investment Advisors LLC now owns 2,336 shares of the exchange traded fund’s stock worth $231,000 after purchasing an additional 125 shares during the last quarter. Denver Wealth Management Inc. raised its holdings in shares of SPDR S&P Biotech ETF by 0.9% during the 3rd quarter. Denver Wealth Management Inc. now owns 14,779 shares of the exchange traded fund’s stock valued at $1,460,000 after purchasing an additional 127 shares in the last quarter. Trust Co. of Vermont lifted its stake in shares of SPDR S&P Biotech ETF by 4.7% in the 3rd quarter. Trust Co. of Vermont now owns 3,058 shares of the exchange traded fund’s stock valued at $302,000 after purchasing an additional 138 shares during the last quarter. Finally, Graypoint LLC boosted its holdings in SPDR S&P Biotech ETF by 5.6% in the third quarter. Graypoint LLC now owns 2,738 shares of the exchange traded fund’s stock worth $271,000 after purchasing an additional 146 shares in the last quarter.

SPDR S&P Biotech ETF Price Performance

SPDR S&P Biotech ETF stock opened at $92.58 on Thursday. SPDR S&P Biotech ETF has a one year low of $81.14 and a one year high of $105.47. The company’s fifty day moving average price is $93.32 and its two-hundred day moving average price is $96.80. The company has a market capitalization of $7.06 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.